Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 4/2024

Open Access 04-04-2024 | Liraglutide | Leading Article

The Pharmacological Landscape for Fatty Change of the Pancreas

Author: Maxim S. Petrov

Published in: Drugs | Issue 4/2024

Login to get access

Abstract

The quest for medications to reduce intra-pancreatic fat deposition is now quarter a century old. While no specific medication has been approved for the treatment of fatty change of the pancreas, drug repurposing shows promise in reducing the burden of the most common disorder of the pancreas. This leading article outlines the 12 classes of medications that have been investigated to date with a view to reducing intra-pancreatic fat deposition. Information is presented hierarchically—from preclinical studies to retrospective findings in humans to prospective interventional studies to randomised controlled trials. This lays the grounds for shepherding the most propitious drugs into medical practice through well-designed basic science studies and adequately powered randomised controlled trials.
Literature
1.
Petrov MS, Taylor R. Intra-pancreatic fat deposition: bringing hidden fat to the fore. Nat Rev Gastroenterol Hepatol. 2022;19:153–68.PubMedCrossRef
2.
Wong VW, Wong GL, Yeung DK, et al. Fatty pancreas, insulin resistance, and β-cell function: a population study using fat-water magnetic resonance imaging. Am J Gastroenterol. 2014;109:589–97.PubMedCrossRef
3.
Lee Y, Hirose H, Ohneda M, et al. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci USA. 1994;91:10878–82.PubMedPubMedCentralCrossRef
4.
Singh RG, Yoon HD, Wu LM, et al. Ectopic fat accumulation in the pancreas and its clinical relevance: a systematic review, meta-analysis, and meta-regression. Metabolism. 2017;69:1–13.PubMedCrossRef
5.
Taylor R, Al-Mrabeh A, Sattar N. Understanding the mechanisms of reversal of type 2 diabetes. Lancet Diabetes Endocrinol. 2019;7:726–36.PubMedCrossRef
6.
Al-Mrabeh A, Zhyzhneuskaya SV, Peters C, et al. Hepatic lipoprotein export and remission of human type 2 diabetes after weight loss. Cell Metab. 2020;31:233–49.PubMedCrossRef
7.
Ko J, Al-Ani Z, Long K, et al. Intra-pancreatic, liver, and skeletal muscle fat depositions in first attack of acute pancreatitis versus health. Am J Gastroenterol. 2022;117:1693–701.PubMedCrossRef
8.
Al-Ani Z, Ko J, Petrov MS. Intra-pancreatic fat deposition across the pancreatitis spectrum and the influence of gut hormones. Dig Liver Dis. 2023;55:1081–90.PubMedCrossRef
9.
Ko J, Skudder-Hill L, Priya S, et al. Associations between intra-pancreatic fat deposition, pancreas size, and pancreatic enzymes in health and after an attack of acute pancreatitis. Obes Facts. 2022;15:70–82.PubMedCrossRef
10.
Sreedhar UL, DeSouza SV, Park B, et al. A systematic review of intra-pancreatic fat deposition and pancreatic carcinogenesis. J Gastrointest Surg. 2020;24:2560–9.PubMedCrossRef
11.
12.
Petrov MS. Fatty change of the pancreas: the Pandora’s box of pancreatology. Lancet Gastroenterol Hepatol. 2023;8:671–82.PubMedCrossRef
13.
14.
Ko J, Skudder-Hill L, Tarrant C, et al. Intra-pancreatic fat deposition as a modifier of the relationship between habitual dietary fat intake and insulin resistance. Clin Nutr. 2021;40:4730–7.PubMedCrossRef
15.
Ko J, Kimita W, Skudder-Hill L, et al. Dietary carbohydrate intake and insulin traits in individuals after acute pancreatitis: effect modification by intra-pancreatic fat deposition. Pancreatology. 2021;21:353–62.PubMedCrossRef
16.
Rossi AP, Fantin F, Zamboni GA, et al. Effect of moderate weight loss on hepatic, pancreatic and visceral lipids in obese subjects. Nutr Diabetes. 2012;2: e32.PubMedPubMedCentralCrossRef
17.
Honka H, Koffert J, Hannukainen JC, et al. The effects of bariatric surgery on pancreatic lipid metabolism and blood flow. J Clin Endocrinol Metab. 2015;100:2015–23.PubMedCrossRef
18.
Umemura A, Sasaki A, Nitta H, et al. Pancreas volume reduction and metabolic effects in Japanese patients with severe obesity following laparoscopic sleeve gastrectomy. Endocr J. 2017;64:487–98.PubMedCrossRef
19.
Lautenbach A, Wernecke M, Riedel N, et al. Adaptive changes in pancreas post Roux-en-Y gastric bypass induced weight loss. Diabetes Metab Res Rev. 2018;34: e3025.PubMedCrossRef
20.
Gaborit B, Abdesselam I, Kober F, et al. Ectopic fat storage in the pancreas using 1H-MRS: importance of diabetic status and modulation with bariatric surgery-induced weight loss. Int J Obes. 2015;39:480–7.CrossRef
21.
Hui SC, Wong SK, Ai Q, Yeung DK, Ng EK, Chu WC. Observed changes in brown, white, hepatic and pancreatic fat after bariatric surgery: evaluation with MRI. Eur Radiol. 2019;29:849–56.PubMedCrossRef
22.
Steven S, Hollingsworth KG, Al-Mrabeh A, et al. Very low-calorie diet and 6 months of weight stability in type 2 diabetes: pathophysiological changes in responders and nonresponders. Diabetes Care. 2016;39:808–15.PubMedCrossRef
23.
Steven S, Hollingsworth KG, Small PK, et al. Weight loss decreases excess pancreatic triacylglycerol specifically in type 2 diabetes. Diabetes Care. 2016;39:158–65.PubMedCrossRef
24.
25.
Lewis GF, Carpentier A, Adeli K, et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev. 2002;23:201–29.PubMedCrossRef
26.
Souza-Mello V, Gregório BM, Cardoso-de-Lemos FS, et al. Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet. Clin Sci (Lond). 2010;119:239–50.PubMedCrossRef
27.
Zsóri G, Illés D, Ivány E, et al. In new-onset diabetes mellitus, metformin reduces fat accumulation in the liver, but not in the pancreas or pericardium. Metab Syndr Relat Disord. 2019;17:289–95.PubMedCrossRef
28.
Kuriyama T, Ishibashi C, Kozawa J, et al. Effects of liraglutide on intrapancreatic fat deposition in patients with type 2 diabetes. Clin Nutr ESPEN. 2024;59:208–13.PubMedCrossRef
29.
Higa M, Zhou YT, Ravazzola M, et al. Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. Proc Natl Acad Sci USA. 1999;96:11513–8.PubMedPubMedCentralCrossRef
30.
Yu X, McCorkle S, Wang M, et al. Leptinomimetic effects of the AMP kinase activator AICAR in leptin-resistant rats: prevention of diabetes and ectopic lipid deposition. Diabetologia. 2004;47:2012–21.PubMedCrossRef
31.
Fernandes-Santos C, Evangelista Carneiro R, de Souza ML, et al. Rosiglitazone aggravates nonalcoholic fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet. Pancreas. 2009;38:e80–6.PubMedCrossRef
32.
Lingvay I, Poduri M, Szczepaniak E, et al. Pioglitazone: effect on pancreatic steatosis and beta cell function. Diabetologia. 2012;55(Suppl 1):S327.
33.
34.
Fang T, Huang S, Chen Y, et al. Glucagon like peptide-1 receptor agonists alter pancreatic and hepatic histology and regulation of endoplasmic reticulum stress in high-fat diet mouse model. Exp Clin Endocrinol Diabetes. 2021;129:625–33.PubMedCrossRef
35.
Kuchay MS, Krishan S, Mishra SK, et al. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Diabetologia. 2020;63:2434–45.PubMedCrossRef
36.
Dutour A, Abdesselam I, Ancel P, et al. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. Diabetes Obes Metab. 2016;18:882–91.PubMedCrossRef
37.
Smits MM, Tonneijck L, Muskiet MH, et al. Pancreatic effects of liraglutide or sitagliptin in overweight patients with type 2 diabetes: a 12-week randomized, placebo-controlled trial. Diabetes Care. 2017;40:301–8.PubMedCrossRef
38.
Vanderheiden A, Harrison LB, Warshauer JT, et al. Mechanisms of action of liraglutide in patients with type 2 diabetes treated with high-dose insulin. J Clin Endocrinol Metab. 2016;101:1798–806.PubMedCrossRef
39.
Svane MS, Johannesen HH, Martinussen C, et al. No effects of a 6-week intervention with a glucagon-like peptide-1 receptor agonist on pancreatic volume and oedema in obese men without diabetes. Diabetes Obes Metab. 2020;22:1837–46.PubMedCrossRef
40.
Nag S, Mandal S, Mukherjee O, et al. Vildagliptin inhibits high fat and fetuin-A mediated DPP-4 expression, intracellular lipid accumulation and improves insulin secretory defects in pancreatic beta cells. Biochim Biophys Acta Mol Basis Dis. 2024;1870: 167047.PubMedCrossRef
41.
Souza-Mello V, Gregório BM, Relvas-Lucas B, et al. Pancreatic ultrastructural enhancement due to telmisartan plus sitagliptin treatment in diet-induced obese C57BL/6 mice. Pancreas. 2011;40:715–22.PubMedCrossRef
42.
Horii T, Kozawa J, Fujita S, et al. Amelioration of pancreatic fat accumulation in Japanese type 2 diabetes patients treated with sodium-glucose cotransporter 2 inhibitors: a retrospective study. Obes Sci Pract. 2021;7:346–52.PubMedPubMedCentralCrossRef
43.
Gaborit B, Ancel P, Abdullah AE, et al. Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study. Cardiovasc Diabetol. 2021;20:57.PubMedPubMedCentralCrossRef
44.
Hummel J, Machann J, Dannecker C, et al. Eight weeks of empagliflozin does not affect pancreatic fat content and insulin secretion in people with prediabetes. Diabetes Obes Metab. 2022;24:1661–6.PubMedCrossRef
45.
Ghosh A, Dutta K, Bhatt SP, et al. Dapagliflozin improves body fat patterning, and hepatic and pancreatic fat in patients with type 2 diabetes in North India. J Clin Endocrinol Metab. 2022;107:e2267–75.PubMedCrossRef
46.
Shi M, Zhang H, Wang W, et al. Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease. J Diabetes Complicat. 2023;37: 108610.CrossRef
47.
Chen ZY, Liu SN, Li CN, et al. Atorvastatin helps preserve pancreatic β cell function in obese C57BL/6 J mice and the effect is related to increased pancreas proliferation and amelioration of endoplasmic-reticulum stress. Lipids Health Dis. 2014;13:98.PubMedPubMedCentralCrossRef
48.
Krisnamurti DGB, Farida S, Putri RC, et al. The effect of simvastatin-Acalypha indica Linn. combination on the improvement of fatty pancreas in rats induced with a high fructose and cholesterol diet. J Adv Vet Anim Res. 2022;9:346–50.PubMedPubMedCentralCrossRef
49.
Wei L, Yamamoto M, Harada M, et al. Treatment with pravastatin attenuates progression of chronic pancreatitis in rat. Lab Investig. 2011;91:872–84.PubMedCrossRef
50.
Patel K, Trivedi RN, Durgampudi C, et al. Lipolysis of visceral adipocyte triglyceride by pancreatic lipases converts mild acute pancreatitis to severe pancreatitis independent of necrosis and inflammation. Am J Pathol. 2015;185:808–19.PubMedPubMedCentralCrossRef
51.
Geer EB, Islam J, Buettner C. Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism. Endocrinol Metab Clin N Am. 2014;43:75–102.CrossRef
52.
Lee JW, Gu HO, Jung Y, et al. Candesartan, an angiotensin-II receptor blocker, ameliorates insulin resistance and hepatosteatosis by reducing intracellular calcium overload and lipid accumulation. Exp Mol Med. 2023;55:910–25.PubMedPubMedCentralCrossRef
53.
54.
Ye T, Chen YH, Gao JH, et al. Effect of octreotide on pancreatic fibrosis in rats with high-fat diet-induced obesity. Int J Clin Exp Pathol. 2018;11:4784–94.PubMedPubMedCentral
55.
Belyaev O, Polle C, Herzog T, et al. Effects of intra-arterial octreotide on pancreatic texture: a randomized controlled trial. Scand J Surg. 2013;102:164–70.PubMedCrossRef
56.
Hong TH, Choi JI, Park MY, et al. Pancreatic hardness: correlation of surgeon’s palpation, durometer measurement and preoperative magnetic resonance imaging features. World J Gastroenterol. 2017;23:2044–51.PubMedPubMedCentralCrossRef
57.
Jeon S, Lee J, Shin Y, Yoon M. Ascorbic acid reduces insulin resistance and pancreatic steatosis by regulating adipocyte hypertrophy in obese ovariectomized mice. Can J Physiol Pharmacol. 2023;101:294–303.PubMedCrossRef
58.
Marciniak SJ, Chambers JE, Ron D. Pharmacological targeting of endoplasmic reticulum stress in disease. Nat Rev Drug Discov. 2022;21:115–40.PubMedCrossRef
59.
60.
Sardar MB, Nadeem ZA, Babar M. Tirzepatide: a novel cardiovascular protective agent in type 2 diabetes mellitus and obesity. Curr Probl Cardiol. 2024;49: 102489.PubMedCrossRef
Metadata
Title
The Pharmacological Landscape for Fatty Change of the Pancreas
Author
Maxim S. Petrov
Publication date
04-04-2024
Publisher
Springer International Publishing
Keyword
Liraglutide
Published in
Drugs / Issue 4/2024
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-024-02022-7

Other articles of this Issue 4/2024

Drugs 4/2024 Go to the issue

AdisInsight Report

Eplontersen: First Approval

AdisInsight Report

Fidanacogene Elaparvovec: First Approval

Correction

Correction: Eplontersen: First Approval

Correction

Correction: Aponermin: First Approval

AdisInsight Report

Aponermin: First Approval

Review Article

Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines